BG103946A - Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак - Google Patents
Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак Download PDFInfo
- Publication number
- BG103946A BG103946A BG103946A BG10394699A BG103946A BG 103946 A BG103946 A BG 103946A BG 103946 A BG103946 A BG 103946A BG 10394699 A BG10394699 A BG 10394699A BG 103946 A BG103946 A BG 103946A
- Authority
- BG
- Bulgaria
- Prior art keywords
- alkyl
- phenyl
- coa reductase
- inhibitor
- hmg coa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4963897P | 1997-06-16 | 1997-06-16 | |
PCT/IB1998/000881 WO1998057633A1 (en) | 1997-06-16 | 1998-06-05 | FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER |
Publications (1)
Publication Number | Publication Date |
---|---|
BG103946A true BG103946A (bg) | 2000-07-31 |
Family
ID=21960890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG103946A BG103946A (bg) | 1997-06-16 | 1999-12-03 | Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак |
Country Status (37)
Country | Link |
---|---|
EP (1) | EP0986387B1 (hu) |
JP (1) | JP3713051B2 (hu) |
KR (1) | KR100392573B1 (hu) |
CN (1) | CN1259868A (hu) |
AP (1) | AP9801261A0 (hu) |
AR (1) | AR013090A1 (hu) |
AT (1) | ATE235905T1 (hu) |
BG (1) | BG103946A (hu) |
BR (1) | BR9810616A (hu) |
CA (1) | CA2294399C (hu) |
CO (1) | CO4950607A1 (hu) |
DE (1) | DE69812933T2 (hu) |
DK (1) | DK0986387T3 (hu) |
DZ (1) | DZ2518A1 (hu) |
EA (1) | EA199901043A1 (hu) |
ES (1) | ES2196559T3 (hu) |
GT (1) | GT199800081A (hu) |
HN (1) | HN1998000091A (hu) |
HR (1) | HRP980328B1 (hu) |
HU (1) | HUP0004624A3 (hu) |
ID (1) | ID23014A (hu) |
IL (1) | IL132765A0 (hu) |
IS (1) | IS5259A (hu) |
MA (1) | MA24569A1 (hu) |
NO (1) | NO996206L (hu) |
NZ (1) | NZ500662A (hu) |
OA (1) | OA11231A (hu) |
PA (1) | PA8453601A1 (hu) |
PE (1) | PE82899A1 (hu) |
PL (1) | PL337651A1 (hu) |
PT (1) | PT986387E (hu) |
SK (1) | SK169699A3 (hu) |
TN (1) | TNSN98088A1 (hu) |
TR (1) | TR199903074T2 (hu) |
UA (1) | UA57081C2 (hu) |
WO (1) | WO1998057633A1 (hu) |
ZA (1) | ZA985182B (hu) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1077949A2 (en) | 1998-05-12 | 2001-02-28 | Warner-Lambert Company | Combinations of protein farnesyltransferase and hmg coa reductase inhibitors and their use to treat cancer |
AU6256499A (en) * | 1998-09-24 | 2000-04-10 | Merck & Co., Inc. | A method of treating cancer |
EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
AU4988100A (en) * | 1999-05-07 | 2000-11-21 | Brigham And Women's Hospital | Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
CA2432137C (en) | 2000-12-19 | 2010-12-21 | Pfizer Products Inc. | Crystal forms of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinolin-2-one, 2,3-dihydroxybutanedioate salts and method of production |
JP4092203B2 (ja) | 2000-12-21 | 2008-05-28 | ニトロメッド,インク. | 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法 |
US20020151563A1 (en) * | 2001-03-29 | 2002-10-17 | Pfizer Inc. | Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth |
US6740757B2 (en) | 2001-08-29 | 2004-05-25 | Pfizer Inc | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer |
JP2005200419A (ja) * | 2004-01-16 | 2005-07-28 | National Health Research Inst | 癌治療法 |
US8168667B2 (en) | 2006-05-31 | 2012-05-01 | Galapagos Nv | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such |
GB2463514C (en) | 2008-09-11 | 2018-09-26 | Galapagos Nv | Imidazolidine compounds and uses therefor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6083985A (en) * | 1995-08-09 | 2000-07-04 | Banyu Pharmaceutical Co., Ltd. | Medicinal composition |
-
1998
- 1998-05-06 UA UA99126842A patent/UA57081C2/uk unknown
- 1998-06-05 EA EA199901043A patent/EA199901043A1/ru unknown
- 1998-06-05 SK SK1696-99A patent/SK169699A3/sk unknown
- 1998-06-05 TR TR1999/03074T patent/TR199903074T2/xx unknown
- 1998-06-05 BR BR9810616-3A patent/BR9810616A/pt not_active Application Discontinuation
- 1998-06-05 WO PCT/IB1998/000881 patent/WO1998057633A1/en not_active Application Discontinuation
- 1998-06-05 CN CN98805968A patent/CN1259868A/zh active Pending
- 1998-06-05 EP EP98921688A patent/EP0986387B1/en not_active Expired - Lifetime
- 1998-06-05 NZ NZ500662A patent/NZ500662A/en unknown
- 1998-06-05 IL IL13276598A patent/IL132765A0/xx unknown
- 1998-06-05 JP JP50403099A patent/JP3713051B2/ja not_active Expired - Fee Related
- 1998-06-05 HU HU0004624A patent/HUP0004624A3/hu unknown
- 1998-06-05 ID IDW991597A patent/ID23014A/id unknown
- 1998-06-05 DK DK98921688T patent/DK0986387T3/da active
- 1998-06-05 KR KR10-1999-7011860A patent/KR100392573B1/ko not_active IP Right Cessation
- 1998-06-05 AT AT98921688T patent/ATE235905T1/de not_active IP Right Cessation
- 1998-06-05 ES ES98921688T patent/ES2196559T3/es not_active Expired - Lifetime
- 1998-06-05 DE DE69812933T patent/DE69812933T2/de not_active Expired - Fee Related
- 1998-06-05 CA CA002294399A patent/CA2294399C/en not_active Expired - Fee Related
- 1998-06-05 PT PT98921688T patent/PT986387E/pt unknown
- 1998-06-05 PL PL98337651A patent/PL337651A1/xx unknown
- 1998-06-09 HN HN1998000091A patent/HN1998000091A/es unknown
- 1998-06-11 AP APAP/P/1998/001261A patent/AP9801261A0/en unknown
- 1998-06-12 PE PE1998000500A patent/PE82899A1/es not_active Application Discontinuation
- 1998-06-12 AR ARP980102812A patent/AR013090A1/es unknown
- 1998-06-15 GT GT199800081A patent/GT199800081A/es unknown
- 1998-06-15 PA PA19988453601A patent/PA8453601A1/es unknown
- 1998-06-15 TN TNTNSN98088A patent/TNSN98088A1/fr unknown
- 1998-06-15 MA MA25114A patent/MA24569A1/fr unknown
- 1998-06-15 ZA ZA9805182A patent/ZA985182B/xx unknown
- 1998-06-15 DZ DZ980128A patent/DZ2518A1/xx active
- 1998-06-16 CO CO98034148A patent/CO4950607A1/es unknown
- 1998-06-16 HR HR980328A patent/HRP980328B1/xx not_active IP Right Cessation
-
1999
- 1999-11-19 IS IS5259A patent/IS5259A/is unknown
- 1999-12-03 BG BG103946A patent/BG103946A/bg unknown
- 1999-12-10 OA OA9900276A patent/OA11231A/en unknown
- 1999-12-15 NO NO996206A patent/NO996206L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100386229B1 (ko) | 히드록시카르바졸화합물의평활근유주및증식의억제 | |
RU2448703C2 (ru) | Онкогенное ras-специфичное цитотоксическое соединение и способы его применения | |
JP6473330B2 (ja) | RalGTPアーゼを標的とする抗がん化合物及びその使用方法 | |
JP4130179B2 (ja) | 骨髄腫を処置するためのc−kit阻害剤の使用 | |
US20070078142A1 (en) | Treatment of tuberous sclerosis associated neoplasms | |
ES2896735T3 (es) | Eflornitina para su uso en el tratamiento del astrocitoma anaplásico recurrente/refractario por temozolomida | |
BG103946A (bg) | Инхибитори на фарнезилтрансфераза в комбинация с инхибитори на нмg соа редуктаза за лечение на рак | |
IL305317A (en) | Preparations and methods for regulating hair growth | |
KR20010032304A (ko) | 알도스 환원효소 억제제 및 글리코겐 포스포릴라제억제제의 혼합물 | |
JP2000510828A (ja) | 腫瘍崩壊剤および放射線療法の臨床効果を増強するためのプロテインキナーゼc阻害剤の使用 | |
JP6864379B2 (ja) | インドール類似体及びその使用 | |
KR20010078803A (ko) | 제약 복합제제 | |
EA001779B1 (ru) | Способ лечения заболеваний, связанных с фактором роста сосудистого эндотелия | |
AU2002211862B2 (en) | Methods of inducing cancer cell death and tumor regression | |
AU724676C (en) | Farnesyl transferase inhibitors in combination with hmg CoA reductase inhibitors for the treatment of cancer | |
US20030114503A1 (en) | Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the treatment of cancer | |
CZ448699A3 (cs) | Inhibitory farnesyltransferasy v kombinaci s inhibitory HMG CoA reduktasy pro léčení rakoviny | |
KR20000035861A (ko) | Aids 치료용 약제를 제조하기 위한 pkc 억제제의 사용 방법 | |
MXPA99011798A (en) | FARNESYL TRANSFERASE INHIBITORS IN COMBINATION WITH HMG CoA REDUCTASE INHIBITORS FOR THE TREATMENT OF CANCER | |
EP3503888A1 (en) | Inhibitors of-bcr-abl mutants and use thereof | |
JP4227121B2 (ja) | 神経因性疼痛治療剤 | |
WO2021086912A1 (en) | Combined pikfyve and p38 map kinase inhibition for treating cancer | |
WO2002078706A1 (en) | Farnesyl transferase inhibitors in combination with hmg coa reductase inhibitors for the inhibition for the treatment of cancer | |
WO2024124000A1 (en) | Treatment of myeloproliferative diseases and disorders with inhibitors of bet family bdii bromodomain | |
EA042675B1 (ru) | Лиганд рецептора гамк-а |